Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4 + T cells

AIDS Research and Human Retroviruses

Volumn 23, Issue 1, 2007, Pages 19-27

  Sankatsing, Sanjay U C ^a,b,c   Cornelissen, Marion ^c   Kloosterboer, Nico ^d   Crommentuyn, Kristel M L ^e   Bosch, Tessa M ^e   Mul, Frederik P ^d   Jurriaans, Suzanne ^c   Huitema, Alwin D R ^e   Beijnen, Jos H ^e   Lange, Joep M A ^a,b   Prins, Jan M ^b   Schuitemaker, Hanneke ^d  

^a International Antiviral Therapy Evaluation Center   (Netherlands)

^b Division of Infectious Diseases   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD45RO ANTIGEN; DIDANOSINE; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ISOLATION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MEMORY CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA SPLICING; VIRUS LOAD; VIRUS REPLICATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NELFINAVIR; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 33846829839     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0027     Document Type: Article

References (33)

1. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
2. Sharom FJ, Yu X, and Doige CA: Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 1993;268:24197-24202.
3. Flexner C: HIV-protease inhibitors. N Engl J Med 1998;338:1281-1292.
4. Clayette P, Jorajuria S, and Dormont D: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:235-236.
5. Gutmann H, Fricker G, Drewe J, Toeroek M, and Miller DS: Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56:383-389.
6. Huisman MT, Smit JW, and Schinkel AH: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-242.
7. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, and Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001;59:806-813.
8. Kim AE, Dintaman JM, Waddell DS, and Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998;286:1439-1445.
9. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
10. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-3601.
11. Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, and Prins JM: P-glycoprotein in Human Immunodefiency Virus 1 Infection and Therapy. Antimicrob Agents Chemother 2004;48:1073-1081.
12. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, and Blaschke TF: The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 2000;28:1058-1062.
13. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, and Back DJ: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001;15:675-681.
14. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, and Back DJ: P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001;15:1353-1358.
15. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Williams I, Back DJ, and Khoo SH: P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002;50:583-588.
16. Saksena NK and Potter SJ:. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev 2003;5:3-18.
17. Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, and Gottesman MM: Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 2000;14:516-522.
18. Speck RR, Yu XF, Hildreth J, and Flexner C: Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002;186:332-340.
19. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, and van der Noordaa J: Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
20. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, Raina JL, Renz H, Gelderblom HR, and Nara PL: Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992;189:695-714.
21. Crommentuyn KM, Rosing H, Nan-Offeringa LG, Hillebrand MJ, Huitema AD, and Beijnen JH: Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2003;38:157-166.
22. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, and te Riele HP: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
23. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, and Pellegrin JL: Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002;16:1331-1340.
24. Solas C, Basso S, Poizot-Martin I, Ravaux I, Gallais H, Gastaut JA, Durand A, and Lacarelle B: High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002;29:374-377.
25. Langmann P, Zilly M, Weissbrich B, Desch S, Vath T, and Klinker H: Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection 2002;30:13-16.
26. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Williams I, Back DJ, and Khoo SH: P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002;50:583-588.
27. Gupta S and Gollapudi S: P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301.
28. Lucia MB, Rutella S, Leone G, Vella S, and Cauda R: HIV-protease inhibitors contribute to p-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 2001;27:321-330.
29. Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, and Haas DW: Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J Acquir Immune Defic Syndr 2003;34:119-126.
30. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, and Wolinsky SM: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
31. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, and Stevenson M: Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000;6:76-81.
32. Fraser C, Ferguson NM, and Anderson RM: Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc Natl Acad Sci USA 2001;98:15167-15172.
33. Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F, Peytavin G, Gerard L, Becquemont L, and Aboulker JP: Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 2005;19:2127-2131.